Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers

@article{Preskorn2007ComparisonOD,
  title={Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers},
  author={Sheldon H. Preskorn and David J Greenblatt and David A. Flockhart and Yan Luo and Elke S. Perloff and Jerold S. Harmatz and Bryan Baker and A Klickdavis and Z Desta and Tal Burt},
  journal={Journal of Clinical Psychopharmacology},
  year={2007},
  volume={27},
  pages={28-34}
}
This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female… 
The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2D6 Substrate Desipramine in Healthy Adults
TLDR
Desvenlafaxine, especially at the recommended therapeutic dose of 50 mg/d for major depressive disorder in the United States, has little potential to interact with CYP2D6 substrates.
Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System
TLDR
Based on the findings presented here, desvenlafaxine is expected to have a low risk for variability in efficacy and safety/tolerability resulting from CYP2D6 polymorphisms or drug-drug interactions when coadministered with CYP1D6 substrates or inhibitors.
An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects
TLDR
Overall, desvenlafaxine had a minimal impact on the PK of desipramine compared with duloxetine, suggesting a lower risk for CYP2D6-mediated drug interactions.
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
TLDR
The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view.
Escitalopram on Plasma Concentrations of Aripiprazole and its Active Metabolite , Dehydroaripiprazole
TLDR
The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view.
The Effect of Coadministration of Duloxetine on Steady-State Serum Concentration of Risperidone and Aripiprazole: A Study Based on Therapeutic Drug Monitoring Data
TLDR
Duloxetine may safely be used concomitantly with risperidone or aripiprazole in psychiatric patients and is found to be a moderate inhibitor of CYP2D6.
Escitalopram Is a Weak Inhibitor of the CYP2D6‐Catalyzed O‐Demethylation of (+)‐Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain
TLDR
Although escitalopram is a weak inhibitor of CYP2D6, it does not impair the analgesic effect of tramadol, and the possibility of a pharmacokinetic (PK) and pharmacodynamic (PD) effect of escITALopram on tramadols metabolism is investigated.
The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
TLDR
Results suggest that no clinically relevant pharmacokinetic interaction occurs when paroxetine and paliperidone ER are co-administered and, therefore, initiation or discontinuation of concomitant treatment with CYP2D6-inhibiting drugs does not appear to warrant an adjustment in paliperidsone ER dosage.
Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.
TLDR
Significant variations exist in metoprolol disposition in hypertensive patients and these differences were more expressed when P450 2D6 phenotype instead of genotype was determined.
...
...

References

SHOWING 1-10 OF 15 REFERENCES
Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
TLDR
When coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramsine at the recommended starting dosages of 50mg/day and 20 mg/ day, respectively.
Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
TLDR
Sertraline had less pharmacokinetic interaction with desipramine than did fluoxetine at their respective, minimum, usually effective doses.
Effect of sertraline on plasma nortriptyline levels in depressed elderly.
TLDR
Overall, a modest effect of sertraline was observed on nortriptyline metabolism in these elderly depressed patients, consistent with prior reports of a weak inhibition of CYP2D6 by sERTraline in vitro and in young healthy volunteers.
Clinical Pharmacokinetics of Sertraline
TLDR
Sertraline is a naphthalenamine derivative with the predominant pharmacological action of inhibiting presynaptic reuptake of serotonin from the synaptic cleft that is well tolerated in therapeutic dosages and relatively safe in overdosage.
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Duloxetine, a potent dual reuptake inhibitor of serotonin and norepinephrine currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
TLDR
S-CT, biotransformed by three CYP isoforms in parallel, is unlikely to be affected by drug interactions or genetic polymorphisms and are also unlikely to cause clinically important drug interactions via CYP inhibition.
Reproducibility of the In Vivo Effect of the Selective Serotonin Reuptake Inhibitors on the In Vivo Function of Cytochrome P450 2D6: An Update (Part I)
  • S. Preskorn
  • Biology, Medicine
    Journal of psychiatric practice
  • 2003
TLDR
This column will provide an update concerning the effects of the selective serotonin reuptake inhibitors (SSRIs) on one specific human drug metabolizing enzyme, cytochrome P450 (CYP) 2D6.
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.
TLDR
The metabolic profiles of some newer antidepressants, the clinical implications of metabolic properties, and research methodology that can be applied in determining which specific human cytochromes P450 (CYP) mediate metabolic pathways are reviewed.
Pharmacogenetic characteristics of the eosinophilia‐myalgia syndrome
TLDR
A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.
...
...